Biomarker & Intervention Discovery

Hypertensive Heart Disease

Pharmacologically actionable gene targets, therapeutic agents ranked by evidence tier, and active clinical trials.

Disease Overview

Spontaneous remission
Not established
Best-intervention remission
Gap size
Primary barrier
Biomarker Targets & Therapeutic Agents

Gene targets queried against DGIdb, Open Targets, ChEMBL, PubMed, and Europe PMC. Agents ranked: ● Clinical > ● Mechanistic > ● Correlative.

ACE 229ADRB1 288AGTR1 249MYH7 3NPPB 0REN 146TGFB1 62
Therapeutic Agent Effect Direction Evidence Tier Potency Source
SALVIANOLIC ACID B ? unclear Mechanistic
CANDOXATRIL ? unclear Mechanistic
CILAZAPRIL inhibits Mechanistic
TP0556351 inhibits Mechanistic
PRAVASTATIN SODIUM ? unclear Mechanistic
SILDENAFIL ? unclear Mechanistic
GEMFIBROZIL ? unclear Mechanistic
RESCINNAMINE ? unclear Mechanistic
SPIRAPRIL ? unclear Mechanistic
INDOMETHACIN ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
ARGIPRESSIN ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
DELAPRIL inhibits Mechanistic
ACETYLCHOLINE ? unclear Mechanistic
THERAPEUTIC GLUCOCORTICOID ? unclear Mechanistic
IMIDAPRIL inhibits Mechanistic
MALATHION inhibits Mechanistic
MOEXIPRIL ? unclear Mechanistic 56.0 nM (IC50)
VORINOSTAT ? unclear Mechanistic
ILEPATRIL inhibits Mechanistic
RXP470.1 inhibits Mechanistic
CGS-27023A ? unclear Mechanistic
NITROPRUSSIDE ? unclear Mechanistic
ENALAPRILAT ANHYDROUS inhibits Mechanistic 1.2 nM (IC50)
TORSEMIDE ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
FOSINOPRIL ? unclear Mechanistic
FUROSEMIDE ? unclear Mechanistic
TEMOCAPRIL HYDROCHLORIDE ? unclear Mechanistic
BENAZEPRIL HYDROCHLORIDE inhibits Mechanistic
CARBARIL inhibits Mechanistic
BUPROPION HYDROCHLORIDE ? unclear Mechanistic
QUINAPRIL ? unclear Mechanistic 8.3 nM (IC50)
COMPOUND 1 [PMID: 24900526] inhibits Mechanistic
COMPOUND 20 [PMID: 22153340] inhibits Mechanistic
BUMETANIDE ? unclear Mechanistic
GALLOPAMIL ? unclear Mechanistic
FLUOXETINE HYDROCHLORIDE ? unclear Mechanistic
AZD6605 inhibits Mechanistic

Showing top 40 of 229 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
BRETYLIUM ? unclear Mechanistic
PINDOLOL activates Mechanistic
BISOPROLOL ? unclear Mechanistic
FLECAINIDE ACETATE ? unclear Mechanistic
METIPRANOLOL ? unclear Mechanistic
METOPROLOL ? unclear Mechanistic
ATENOLOL inhibits Mechanistic
BUCINDOLOL HYDROCHLORIDE inhibits Mechanistic
METIPRANOLOL HYDROCHLORIDE inhibits Mechanistic
ALPRENOLOL ? unclear Mechanistic 4.88 nM (IC50)
PRACTOLOL inhibits Mechanistic
XAMOTEROL activates Mechanistic
PENBUTOLOL ? unclear Mechanistic
DOBUTAMINE ? unclear Mechanistic
BETHANIDINE ? unclear Mechanistic
BETAXOLOL ? unclear Mechanistic 37.1 nM (IC50)
MURAGLITAZAR ? unclear Mechanistic
ACEBUTOLOL ? unclear Mechanistic
LABETALOL HYDROCHLORIDE inhibits Mechanistic
ACEBUTOLOL HYDROCHLORIDE inhibits Mechanistic
NOREPINEPHRINE ? unclear Mechanistic
OT-730 ? unclear Mechanistic
CARVEDILOL inhibits Mechanistic
NADOLOL inhibits Mechanistic
LEVOBUNOLOL inhibits Mechanistic
LABETALOL ? unclear Mechanistic
TERTATOLOL ? unclear Mechanistic
ARBUTAMINE ? unclear Mechanistic
PROPRANOLOL HYDROCHLORIDE inhibits Mechanistic
ZIPRASIDONE ? unclear Mechanistic
BUPRANOLOL ? unclear Mechanistic
LANDIOLOL inhibits Mechanistic
OXPRENOLOL ? unclear Mechanistic
MEPINDOLOL ? unclear Mechanistic
CELIPROLOL inhibits Mechanistic
BISOPROLOL FUMARATE inhibits Mechanistic
DESIPRAMINE ? unclear Mechanistic
DOPAMINE activates Mechanistic
ISOPROTERENOL activates Mechanistic
DOBUTAMINE HYDROCHLORIDE activates Mechanistic

Showing top 40 of 288 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
CANDESARTAN CILEXETIL inhibits Mechanistic
CHEMBL:CHEMBL586135 ? unclear Mechanistic
VALSARTAN inhibits Mechanistic 4700.0 nM (Ki)
EPROSARTAN MESYLATE inhibits Mechanistic
FIMASARTAN inhibits Mechanistic
ASCORBIC ACID ? unclear Mechanistic
OLMESARTAN MEDOXOMIL inhibits Mechanistic
AZILSARTAN MEDOXOMIL inhibits Mechanistic
THERAPEUTIC ANDROSTANOLONE ? unclear Mechanistic
CHEMBL:CHEMBL347610 ? unclear Mechanistic
CHEMBL:CHEMBL421088 ? unclear Mechanistic
LOSARTAN POTASSIUM inhibits Mechanistic 5.5 nM (IC50)
CHEMBL:CHEMBL1492017 ? unclear Mechanistic
SPARSENTAN inhibits Mechanistic
SODIUM CHLORIDE ? unclear Mechanistic
CHEMBL:CHEMBL261693 ? unclear Mechanistic
CHEMBL:CHEMBL1972216 ? unclear Mechanistic
EPROSARTAN ? unclear Mechanistic 7.3 nM (IC50)
C-FOS ANTISENSE ? unclear Mechanistic
SARALASIN ACETATE inhibits Mechanistic
IRBESARTAN inhibits Mechanistic 1.1 nM (Ki)
DISULFIRAM ? unclear Mechanistic
SAPRISARTAN ? unclear Mechanistic
H2O2 ? unclear Mechanistic
CHEMBL:CHEMBL591834 ? unclear Mechanistic
CAPTOPRIL ? unclear Mechanistic
ANGIOTENSIN II ? unclear Mechanistic
CHEMBL:CHEMBL400912 ? unclear Mechanistic
ATORVASTATIN CALCIUM TRIHYDRATE ? unclear Mechanistic
IDOXIFENE ? unclear Mechanistic
CHEMBL:CHEMBL528694 ? unclear Mechanistic
IL-6 ? unclear Mechanistic
ANGIOTENSIN II ACETATE activates Mechanistic
LEVODOPA ? unclear Mechanistic
GAMMA-INTERFERON ? unclear Mechanistic
AZILSARTAN KAMEDOXOMIL inhibits Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
CHEMBL:CHEMBL1445650 ? unclear Mechanistic
MUSCLE RELAXANT ? unclear Mechanistic
CL-329167 ? unclear Mechanistic

Showing top 40 of 249 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MAVACAMTEN inhibits Mechanistic
OMECAMTIV MECARBIL activates Mechanistic
DANICAMTIV activates Mechanistic

Pipeline results not yet available for this target. Run the pipeline to populate.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
MURAGLITAZAR ? unclear Mechanistic
HYDROCHLOROTHIAZIDE ? unclear Mechanistic
IMARIKIREN HYDROCHLORIDE inhibits Mechanistic
1.ALPHA.-HYDROXYVITAMIN D5 ? unclear Mechanistic
ALISKIREN FUMARATE inhibits Mechanistic
TERLAKIREN ? unclear Mechanistic
SITOKIREN inhibits Mechanistic
REMIKIREN ? unclear Mechanistic
ALISKIREN ? unclear Mechanistic
VTP-27999 ? unclear Mechanistic
CHEMBL47918 inhibits Mechanistic 30.0 nM (IC50)
CHEMBL50217 inhibits Mechanistic 2.2 nM (IC50)
CHEMBL301347 inhibits Mechanistic 2.5 nM (IC50)
CHEMBL48624 inhibits Mechanistic 2.4 nM (IC50)
CHEMBL101874 inhibits Mechanistic 1400.0 nM (IC50)
CHEMBL300504 inhibits Mechanistic 67.0 nM (IC50)
CHEMBL49225 inhibits Mechanistic 2.1 nM (IC50)
CHEMBL49218 inhibits Mechanistic 1.3 nM (IC50)
CHEMBL297129 inhibits Mechanistic 1.5 nM (IC50)
CHEMBL49286 inhibits Mechanistic 1.0 nM (IC50)
CHEMBL318242 inhibits Mechanistic 1200.0 nM (IC50)
CHEMBL297701 inhibits Mechanistic 2.7 nM (IC50)
CHEMBL49379 inhibits Mechanistic 1.3 nM (IC50)
CHEMBL295048 inhibits Mechanistic 2.5 nM (IC50)
CHEMBL46240 inhibits Mechanistic 110.0 nM (IC50)
CHEMBL301395 inhibits Mechanistic 1.7 nM (IC50)
CHEMBL295838 inhibits Mechanistic 1.3 nM (IC50)
CHEMBL300711 inhibits Mechanistic 1.5 nM (IC50)
CHEMBL301966 inhibits Mechanistic 2.4 nM (IC50)
CHEMBL48591 inhibits Mechanistic 1.5 nM (IC50)
CHEMBL97865 inhibits Mechanistic 69000.0 nM (IC50)
CHEMBL46115 inhibits Mechanistic 0.9 nM (IC50)
CHEMBL265560 inhibits Mechanistic 2.7 nM (IC50)
CHEMBL51935 inhibits Mechanistic 17.0 nM (IC50)
CHEMBL48481 inhibits Mechanistic 6.0 nM (IC50)
CHEMBL98582 inhibits Mechanistic 4600.0 nM (IC50)
CHEMBL301146 inhibits Mechanistic 5.0 nM (IC50)
CHEMBL321937 inhibits Mechanistic 280.0 nM (IC50)
CHEMBL49172 inhibits Mechanistic 2.0 nM (IC50)
CHEMBL51401 inhibits Mechanistic 1.0 nM (IC50)

Showing top 40 of 146 agents ranked by evidence tier.

Therapeutic Agent Effect Direction Evidence Tier Potency Source
INTERFERON ALFA-2B ? unclear Mechanistic
PIOGLITAZONE HYDROCHLORIDE ? unclear Mechanistic
SILYMARIN ? unclear Mechanistic
RITUXIMAB ? unclear Mechanistic
VERAPAMIL ? unclear Mechanistic
PROTEASOME INHIBITOR ? unclear Mechanistic
FRESOLIMUMAB ? unclear Mechanistic
ATENOLOL ? unclear Mechanistic
BINTRAFUSP ALFA ~ modulates Mechanistic
NISEVOKITUG ? unclear Mechanistic
LUSPATERCEPT inhibits Mechanistic
TRETINOIN ? unclear Mechanistic
HYDROCORTISONE BUTYRATE ? unclear Mechanistic
VITAMIN E ? unclear Mechanistic
IRINOTECAN HYDROCHLORIDE ? unclear Mechanistic
INOSITOL ? unclear Mechanistic
NICOTINE POLACRILEX ? unclear Mechanistic
FENRETINIDE ? unclear Mechanistic
MELATONIN ? unclear Mechanistic
ISOTRETINOIN ? unclear Mechanistic
VACTOSERTIB ? unclear Mechanistic 12.9 nM (IC50)
TRIAMCINOLONE ? unclear Mechanistic
TAMOXIFEN ? unclear Mechanistic
ADRIAMYCIN ? unclear Mechanistic
HEPARAN SULFATE ? unclear Mechanistic
GOSSYPOL ? unclear Mechanistic
TCDD ? unclear Mechanistic
AMIFOSTINE ANHYDROUS ? unclear Mechanistic
RAMIPRIL ? unclear Mechanistic
ANTIOXIDANT ? unclear Mechanistic
SOTATERCEPT ? unclear Mechanistic
ASPIRIN ? unclear Mechanistic
GALUNISERTIB ? unclear Mechanistic
KEYHOLE LIMPET HEMOCYANIN ? unclear Mechanistic
PIRFENIDONE ? unclear Mechanistic
H2O2 ? unclear Mechanistic
THERAPEUTIC ANDROGEN ? unclear Mechanistic
SANDOSTATIN ? unclear Mechanistic
BROXURIDINE ? unclear Mechanistic
DISITERTIDE ? unclear Mechanistic

Showing top 40 of 62 agents ranked by evidence tier.


Clinical Trials

Recruiting and recently completed trials from ClinicalTrials.gov. Data retrieved 2026-07-03.

NCT06186102 Phase: PHASE2 Started: 2024-01-01

The present study is testing spermidine treatment in elderly patients with coronary artery disease. The study is a randomized, double-blind, placebo-controlled, two-armed, parallel-group, single centre, clinical study.

NCT07676656 Phase: N/A Started: 2025-02-28

aim of this study was to evaluate the relationship between multiple conventional and novel anthropometric measurements and hypertension in patients presenting to the ED with ACS and whether anthropometric indices differ according to admission BP status and evaluated the relationship between regional...

NCT05839028 Phase: N/A Started: 2022-10-16

The main goal of our investigation is to study the mechanisms of formation of left ventricular remodeling in patients with hypertension, working on a rotational expedition basis in the Arctic.

NCT06295848 Phase: NA Started: 2022-11-15

The aim of this study is to investigate the beneficial impacts of the 6-week standardized CR program applied to hypertensive RA patients whose disease activity is under control with regular pharmacological treatment. Subjects will be randomly assigned to one of two groups: 1.) standard of care (SOC...

NCT05655936 Phase: NA Started: 2023-06-29

This is a single site, single-blinded parallel randomized control trial that investigates a multi-level intervention to improve postpartum blood pressure in women with hypertensive disorder pregnancy. The investigators will recruit women diagnosed with a hypertensive disorder of pregnancy, identifie...

NCT01047735 Phase: NA Started: 2009-09-01

This research study is being performed to begin to determine the effectiveness of two dominant bariatric surgery procedures versus an intensive lifestyle intervention to induce weight loss in patients and promote improvements in Type 2 diabetes mellitus (T2DM) in moderately obese patients. T2DM is ...

NCT06523569 Phase: NA Started: 2024-11-07

The purpose of this research is to study digital health interventions to prevent cardiovascular disease in individuals who have had a hypertensive disorder of pregnancy (HDP).

NCT07544888 Phase: PHASE1 Started: 2025-11-01

Hypertension is a major global health problem, affecting about 30% of people and up to two-thirds of those over 60 years. Its prevalence has increased significantly, with over one billion adults affected worldwide and expected to reach 1.56 billion by 2025, especially in developing countries where e...

NCT06735599 Phase: NA Started: 2024-09-17

The purpose of the study is to determine the effectiveness of wild blueberries on cardiovascular health, cognitive function, and gut microbiota composition in non-Hispanic Black and White adults with elevated blood pressure.

NCT07482462 Phase: N/A Started: 2025-10-15

The goal of this observational study is to assess arterial stiffness and autonomic regulation of blood pressure and heart rate in healthy adults and people with arterial hypertension during orthostatic stress and graded physical exercise. The main objective is to analyze cardiovascular responses to ...

NCT04849312 Phase: N/A Started: 2017-06-01

This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict the likelihood of 30-day readmission throughout a patient's admission. T...

NCT05045742 Phase: N/A Started: 2021-03-20

This is a retrospective observational study drawing on data from the Brigham and Women's Home Hospital database. Sociodemographic and clinic data from a training cohort were used to train a machine learning algorithm to predict patient deterioration throughout a patient's admission. This algorithm w...

NCT03524222 Phase: NA Started: 2018-01-18

The investigators propose a home hospital model of care that substitutes for treatment in an acute care hospital. Limited studies of the home hospital model have demonstrated that a sizeable proportion of acute care can be delivered in the home with equal quality and safety, reduced cost, and improv...

NCT04763629 Phase: NA Started: 2021-01-20

The study aim is to compare the effects produced by two different exercise training modalities on short-term blood pressure variability and atrial function evaluated by speckle-tracking echocardiography in hypertensive patients with ischemic heart disease. 50 males patients will be randomized to int...

NCT07270718 Phase: NA Started: 2025-01-24

Objective: to evaluate the effectiveness of using a food product, dry finely dispersed beetroot powder in a dose of 20 g, containing 800 mg of nitrate (NO3-), in relation to the regulation of blood pressure in men with hypertension who reached the target blood pressure level while taking optimal ant...


Agents Found By Disease-Level Search

Searched directly from “Hypertensive Heart Disease” via ClinicalTrials.gov interventions and Open Targets' disease→drug data — independent of the 7-gene target panel above. This surfaces agents whose mechanism doesn't route through a curated gene (combination therapies, standard-of-care drugs, targets outside the panel).

Not yet run. python -m biomarker_pipeline.run_disease_agent_discovery --disease "..."

Part of the Open Source Medicine Foundation Network

Open Source Medicine Foundation The OSMF hub — advancing open-source biomedical research infrastructure, tools, and evidence synthesis.
SpikeProtein.site Database and research resource on SARS-CoV-2 spike protein biology, persistence, and clinical implications.
Vaccine Data Navigator Open-access navigation tool for vaccine adverse event reporting and surveillance data.
PACVS Research Summit Annual summit convening researchers, clinicians, and patients on PACVS science.